Start with its own history
Compare positive annual observations to understand how this company has been priced over time. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NASDAQ · TRIBMedical - SpecialtiesUpdated Nov 4, 2026
Trinity Biotech plc P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
N/M
No meaningful positive P/E available.
Share price6.4275
÷Earnings per share-60.6
Price and EPS in quote currency. Calculation details
Zero or negative earnings do not produce a meaningful conventional P/E.
P/E over time
2016 – 2025
Annual P/ESelected-period average 27.07×
3-year averageN/M0 positive annual observations
5-year average34.05×1 positive annual observations
10-year average27.07×2 positive annual observations
Peer median · TTM2.47×2 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2025 | N/M | N/M |
| Dec 31, 2024 | N/M | N/M |
| Dec 31, 2023 | N/M | N/M |
| Dec 31, 2022 | N/M | N/M |
| Dec 31, 2021 | 34.05× | N/M |
| Dec 31, 2020 | N/M | N/M |
| Dec 31, 2019 | N/M | N/M |
| Dec 31, 2018 | 20.09× | N/M |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2017 | N/M | N/M |
| Dec 31, 2016 | N/M | N/M |
| Dec 31, 2015 | 61.25× | -46.8% |
| Dec 31, 2014 | 115.20× | -59.7% |
| Dec 31, 2013 | 285.68× | +220.9% |
| Dec 31, 2012 | 89.01× | +27.7% |
| Dec 31, 2011 | 69.73× | +351.1% |
| Dec 31, 2010 | 15.46× | +72.9% |
| Dec 31, 2009 | 8.94× | N/M |
| Dec 31, 2008 | N/M | N/M |
| Dec 31, 2007 | N/M | N/M |
| Dec 31, 2006 | 214.25× | +89.0% |
| Dec 31, 2005 | 113.33× | +206.3% |
| Dec 31, 2004 | 37.00× | -31.0% |
| Dec 31, 2003 | 53.65× | +281.5% |
| Dec 31, 2002 | 14.06× | -73.6% |
| Dec 31, 2001 | 53.33× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How TRIB compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 TRIB This stockTrinity Biotech plc | N/M |
 ADVBAdvanced Biomed Inc. Common Stock | 4.49× |
 BGLCBioNexus Gene Lab Corp. | N/M |
 XAIRBeyond Air, Inc. | N/M |
 MRKRMarker Therapeutics, Inc. | N/M |
 CHEKCheck-Cap Ltd. | 0.45× |
 GBSGBS Inc. | N/M |
 SINTSintx Technologies, Inc. | N/M |
 EVGNEvogene Ltd. | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does TRIB’s P/E tell you?
Compare like with like
The median of the 2 positive peer ratios above is 2.47×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take TRIB into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("TRIB", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
A conventional P/E is not meaningful when earnings are zero or negative. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 4, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
TRIB P/E ratio: common questions
The essentials behind the numbers.
Trinity Biotech plc does not currently have a meaningful positive P/E in the quote data. A zero or negative EPS makes the conventional P/E unsuitable for comparison.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.